Fig. 3.
Effects of colchicine on individual components of MACE. Colchicine significantly lowered the risk of ACS (OR 0.49; 95% CI 0.27–0.89), MI (OR 0.77; 95% CI 0.62–0.95), unstable angina (OR 0.39; 95% CI 0.19–0.77), and coronary revascularization (OR 0.70; 95% CI 0.49–0.99). There appeared to be a lower risk of ischemic stroke of borderline statistical significance (OR 0.82; 95% CI 0.64–1.05). Heterogeneity ranged from low to moderate (I2 = 26–72%). ACS acute coronary syndrome, CI confidence interval, MACE major adverse cardiovascular events, MI myocardial infarction, OR odds ratio
